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1. Introduction
Cervical cancer is the third most commonly diagnosed cancer and the fourth leading cause
of cancer death in women worldwide, with an estimated 529,000 new cases and 275,000
deaths expected to occur in 2008, of which about 80% occurred in developing countries (Fer‐
lay et al., 2010). Western countries have experienced dramatic reductions in the incidence of
and mortality from invasive cervical cancer (Day, 1984; Hristova & Hakama, 1997; Duguid,
Duncan, & Currie, 1985; Taylor et al., 2001). In developed countries, incidence rates of cervi‐
cal cancer are generally low and accounts for only 3.6% (Bray et al., 2005). The dispropor‐
tionate burden of cervical cancer in developing countries and elsewhere in medically
underserved populations is mainly due to lack of effective screening program (Hristova &
Hakama, 1997; Duguid, Duncan, & Currie, 1985; Taylor et al., 2001).
Cervical cancer is almost completely preventable, because unlike many cancers, which are
caused by a number of physical, genetic, lifestyle and environmental factors, almost all cer‐
vical cancer is caused by a sexually transmitted virus, the human papillomavirus (HPV)
(Kari & Mark, 2008). Over the past decades, scientists, public health researchers, clinicians,
policymakers, women’s health and cancer advocates and private sector partners have
worked tirelessly to raise global awareness of cervical cancer. They have identified and de‐
veloped high-impact low-cost solutions to prevent this devastating disease. Today, there are
a combination of new and affordable high-tech tools and effective simple solutions.
© 2013 Rahman et al.; licensee InTech. This is an open access article distributed under the terms of the
Creative Commons Attribution License (http://creativecommons.org/licenses/by/3.0), which permits
unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
The purpose of this chapter is to explore the opportunities to limit the epidemic by (a) exam‐
ining the causes, signs and symptoms and complications of cervical cancer (b) reviewing the
epidemiology of cervical cancer in the developed region, and (c) prevention of cervical can‐
cer strategy in the developed countries.
2. Disease issues
2.1. Risk factors of cervical cancer
Basically every woman who has ever been sexually active can develop cancer of the cervix.
A vast 99% of cervical cancers are caused by HPV (Kari & Mark, 2008). Of the more than 100
types of HPV, most are benign and resolve without intervention. Visible lesions or warts,
known as condylomata acuminate, may be seen. High-risk HPV types tend to persist and
are associated with development of precancerous lesions and cervical cancer. Although cer‐
vical cancer is associated with about 15 high-risk HPV types, invasive cervical cancer is pre‐
dominantly caused by HPV 16 and 18 (Tiffen & Mahon 2006).
2.1.1. Other factors thought to be associated with cancer of the cervix
2.1.1.1. Marital and sexual factors
The epidemiologists have noted that risk of cervical cancer is strongly influenced by sexual
behavior. This has led to discovery of the role of HPV infection. Studies have shown in‐
creased risk due to marriage at young age, onset of regular sex at an early age <20yrs, multi‐
ple lifetime number of sexual partners (Karlsson et al., 1995). These risk factors remain
significant especially among those women without apparent human papilloma virus infec‐
tion (HPV). Frequency of intercourse has not been found to be a risk factor after accounting
for the effects of number of sexual partners.
2.1.1.2. The role of the male sexual partner
In most studies, the husbands of the cervical cancer patients were found to report more sex‐
ual partners, history of various genital infections like venereal warts, gonorrhea and herpes
simplex genitalis compared to husbands of control subjects. Frequent use of condoms was
associated with a lower risk for cancer of the cervix (Miller, Blumenthal & Blanchard, 2004).
2.1.1.3. Gynecological and obstetric events
Multiparity with short intervals between pregnancies (<2 yrs) has been consistently shown
to increase the risk of cervical cancer (Hsieh et al., 1999). There is little evidence to show that
the risk of cervical cancer is affected by age at menarche and menopause, characteristics of
menses or personal hygiene (Smith et al., 2003).
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2.1.1.4. Contraceptive methods
Recent research is showing that long-term users of oral contraceptives are at excess risk for
cervical cancer, even after adjusting for sexual and social factors. The risk may be stronger
for adenocarcinoma than squamous cell neoplasm (Smith et al., 2003).
2.1.1.5. Genetic factors
Although some reports suggest that a familial tendency does exist, but there is still little at‐
tention to it (Horng et al., 2004). Whether this tendency reflects environmental or genetic fac‐
tors is unknown.
2.1.1.6. Dietary factors
Micronutrients (e.g. carotenoids, vitamin C and folate) are thought to have a protective ef‐
fect to cervical cancer by promoting the regression of low grade squamous intra-epithelial
lesion (SIL). Some components of fruits and vegetables have been suggested to be protective
too (Hermandez et al., 2003).
2.1.1.7. Smoking
Some case control studies and a cohort investigation have demonstrated increased risk of
cervical cancer and SIL among smokers even after controlling for most other risk factors.
However, the smoking effect is restricted to squamous cell carcinoma and not among other
histological types (Clifford et al., 2005). Smoking is strongly associated with high risk of cer‐
vical HPV infection because of correlation between smoking and sexual behavior (Clifford et
al., 2005).Therefore, HPV status can confound studies of smoking and cervical cancer.
2.2. Infections other than HPV
HPV may not be the only agent involved in causation of cervical cancer. Of the other agents
examined, most attention has been focused on herpes simplex virus type 2 (HSV-2) and
Chlamydia which have been shown to increase the risk (Smith et al., 2002). One of the stud‐
ies conducted in Uganda showed an increased risk of cervical cancer with multiple and con‐
current infections, thus addressing the hypothesis that chronic cervico vaginal infection may
increase the risk of HPV leading to cancer of the cervix (Schmauz et al., 1989). HIV infection
is another viral infection which has been found to increase the risk of high grade lesions of
the cervix and thus increasing risk of cancer of the cervix too. The effect is much higher
among patients with both HIV and HPV (possible interaction). This may explain why the
younger women are reporting with advanced cancer of the cervix.
2.3. Signs and symptoms
Symptoms usually do not appear until abnormal cervical cells become cancerous and invade
nearby tissue. When this happens, the most common symptom is abnormal vaginal bleed‐
ing. Bleeding may start and stop between regular menstrual periods, or it may occur after
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sexual intercourse, douching, or a pelvic exam (Kumar et al., 2007). Menstrual bleeding may
last longer and be heavier than usual. Bleeding after menopause or increased vaginal dis‐
charge may also be symptoms of cervical cancer.
2.4. Complications of cancer of the cervix
The common ones include: severe anemia as a result of severe or chronic on and off bleeding
from the cervix; kidney complications and later kidney failure (renal failure with hydro‐
nephrosis) due to obstruction of the ureters by the infiltrating cancer which continues to
spread to the pelvic walls; vesico vaginal fistula (communication between the urinary blad‐
der and vagina) and rectal vaginal fistula (communication between rectum and vagina); and
severe pain as a result of infiltration of the sacral nerves (Canavan & Doshi, 2000). Mortality
is commonly due to anemia and Uremia (due to kidney failure).
3. Epidemiological issues
3.1. Cervical cancer: Burden of disease in the developed regions
Estimated incidence and mortality of cervical cancers in 2008 varied widely between coun‐
tries in each developed regions (Table 1). Highest incidence rates for this cancer within the
European region were recorded for Hungry (16.6/100, 00) followed by Czech Republic
(13.8/100,000), and Poland (12.3/100,000), with lowest incidence rates in Finland, Greece, and
Switzerland and Greece. Death rates due to cervical cancer are highest in Poland (6.2/100,
00) and lowest in Finland and Switzerland within the developed countries of European re‐
gion (Table 1).
The lowest incidence (1.7/100,000) and mortality rate (5.7/100,000) from cervical cancer was
registered in United States, while Canada had the highest incidence (6.6/100,000) and mor‐
tality rate (1.9/100,000), within the North America region (Table 1). Within the South Ameri‐
ca and Middle East region, Brazil and Israel had the highest incidence and mortality rate
due to cervical cancer. A wide variation of cervical cancer incidence and mortality rate is ob‐
served among countries from the developed countries of Asia and the Pacific, whre highest
incidence (10.8/100,000) and mortality rate (2.7/100,000) was registered in Republic of Korea
(South Korea), while Australia had the lowest incidence (4.9/100,000) and mortality rate
(1.4/100,000) (Table 1).
Region/Country Annual incidence rates per 100,000 Annual cervical cancer deaths per 100,000
Europe
Belgium 9.4 2.7
Czech Republic 13.8 4.2
Denmark 11.0 2.5
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Region/Country Annual incidence rates per 100,000 Annual cervical cancer deaths per 100,000
Finland 3.7 0.9
France 7.1 1.8
Germany 6.9 2.3
Hungry 16.6 5.8
Iceland 6.3 1.6
Ireland 10.9 3.1
Italy 6.7 1.5
Luxemburg 6.3 1.9
Netherlands 5.4 1.5
Norway 9.3 2.3
Poland 12.3 6.2
Portugal 12.2 3.6
Spain 6.3 1.9
Sweden 7.4 1.8
Switzerland 4.0 0.9
United kingdom 7.2 2.0
North America
Canada 6.6 1.9
United States 5.7 1.7
South America
Brazil 24.5 10.9
Uruguay 16.5 6.8
Middle East
Israel 5.6 2.1
Saudi Arabia 2.1 0.8
Turkey 4.2 1.6
Asia/Pacific
Australia 4.9 1.4
Japan 9.8+ 2.6
Republic of Korea 10.8 2.7
New Zealand 5.5 1.6
Source: Globocan 2008, International Agency for Research on Cancer
Table 1. Age-adjusted cervical cancer incidence and mortality rates for 2008 for 31 developed countries
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3.2. Cervical cancer incidence in United Kingdom
Cervical cancer is the 9th most common cancer in the UK in 2009, accounting for 1% of all
new cases and it is the11th most common cancer among women in the UK, accounting for
around 2% of all new cases of cancer in females (Cancer Statistics Registrations, England,
2011). In 2009, there were 3,378 new cases of cervical cancer in the UK (Table 2). The crude
incidence rate shows that there are around 11 new cervical cancer cases for every 100,000
females in the UK. The European age-standardized incidence rates (AS rates) of cervical can‐
cer are significantly higher in Northern Ireland compared with England (Table 2). However,
the rates do not differ significantly between the other countries.
England Wales Scotland Northern Ireland United Kingdom
Cases 2,747 186 326 119 3,378
Crude rate 10.4 12.1 12.2 13.1 10.8
AS rate 9.8 11.4 11.2 12.9 10.1
AS rate-95% LCL* 9.4 9.8 10.0 10.6 9.8
AS rate-95% UCL** 10.2 13.0 12.4 15.2 10.5
** 95% LCL and 95% UCL are the 95% lower and upper confidence limits around the age standardized rate (AS rate)
Source: Cancer Research, United Kingdom
Table 2. Cervical Cancer, Number of New Cases, Crude and European Age-Standardized (AS) Incidence Rates per
100,000 Population, Females, UK, 2009
3.2.1. Trends of cervical cancer incidence in the United Kingdom over time
Cervical cancer incidence rates decreased dramatically since the late 1980s following the in‐
troduction of the national NHS cervical screening programs around the UK in 1988. Rates
then reached a plateau in the early 2000s (shown for Great Britain in Figure 1). Rates de‐
creased by 49% in Great Britain from their peak in 1985-1987 (at 16.3 per 100,000 women) to
the lowest rate in 2002-2004 (at 8.4 per 100,000 women). This is because cervical screening
detects and treats abnormal cells, and so can help prevent many cases of cervical cancer
from ever developing (Thompson et al., 2010).
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Figure 1. Cervical cancer: European age-standardized incidence rates, females, Great Britain, 1975-2009. Source: Can‐
cer Research, UK
The age-standardized incidence rate for the UK initially shows a similar downward trend
from 1993 onwards (Figure 2). However, since 2002-2004, the incidence rate has been increas‐
ing by more than 9% (from 8.4 in 2002-2004 to 9.2 in 2007-2009). Between 2008 and 2009 there
was an increase in the age specific incidence rate of 14% for all ages in the UK (Figure 2).
Figure 2. Cervical cancer: European age-standardized incidence rates, females, UK, 1993-2009. Source: Cancer Re‐
search, UK
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3.3. Cervical cancer incidence in United States
Cervical cancer used to be the leading cause of cancer death for women in the United States.
However, in the past 40 years, the number of cases of cervical cancer and the number of
deaths from cervical cancer have decreased significantly. This decline largely is the result of
many women getting regular Pap tests, which can find cervical pre cancer before it turns in‐
to cancer. It is estimated that 12,170 women will be diagnosed with and 4,220 women will
die of cancer of the cervix uteri in 2012.
Although cervical cancer incidence and mortality rates have declined approximately 50% in
the United States over the past three decades, the disease remains a serious health threat.
There are large differences in the rates of new cases of and deaths from cervical cancer
among women from different racial and ethnic groups in the United States. Death rates of
cervical cancer for older Black women are nearly three times greater than those for White
women of the same age group (Figure 3). Older Hispanic women, Asian women and Ameri‐
can Indian/Alaska Native women also have much higher death rates from cervical cancer
than do White women.
Figure 3. Mortality rate due to cervical cancer by race and age in United States. Source: National Cancer Institute, SEER
data: Cancer Statistics Branch, released April 2006.
4. Prevention of cervical cancer
Cervical cancer is one of the most preventable types of cancer. The following preventive
measures can be undertaken to help cross- out the cervical cancer: primary prevention and
secondary prevention
4.1. Vaccines as primary prevention
By 2007 two prophylactic vaccines, both highly effective against oncogenic HPV types 16
and 18, available in industrialized countries. Between June and October 2006, a quadrivalent
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HPV vaccine protective against HPV types 6, 11, 16 and 18 (Gardasil®, Merck) was licensed
for use first by the US regulatory authorities and then by the European Commission (EC).
EC approval for a bivalent vaccine protective against HPV types 16 and 18 (Cervarix®, Glax‐
oSmithKline Biologicals) is expected to follow (Harper et al., 2004; Villar et al., 2005) Clinical
trial data to date suggest a minimum of four to five years’ efficacy of close to 100% in pre‐
venting persistent infection and precancerous cervical abnormalities (cervical dysplasia)
caused by type-specific disease. However, the vaccines are given in a series of three 0.5 ml
intramuscular injections over a six month period, and duration of response is only available
for the complete series (Harper et al., 2006).
In addition, women vaccinated with the bivalent vaccine had a 94% reduction in new infec‐
tions with two other oncogenic HPV types, while those vaccinated with the quadrivalent
formulation showed a measurable antibody response to those same additional types, giving
evidence of cross-protection (Harper et al., 2006; Smith et al., 2006). One model suggests that
a vaccine with 98% efficacy against HPV-16 and 18 could, within 40 to 50 years, reduce cer‐
vical cancer incidence by 51% if all adolescent girls were vaccinated before initiation of sexu‐
al activity (Goldie et al., 2003). The actual impact of the vaccine will be highly dependent on
country-specific parameters, including the capacity to deliver current vaccines that require
three consecutive doses, cold chain management and a possible booster dose year later
(Lowndes, & Gill, 2005).
The new vaccine is designed to prevent cervical cancer by stimulating the body’s immune
system to make antibodies that will prevent the virus from infecting the woman. Unlike
many vaccines that may contain live or killed virus particles, the HPV vaccine does not con‐
tain any genetic material responsible for creating warts, dysplasia or cancer (Anne-Sophie et
al., 2011). Instead, the HPV virus is made up of the outer protein coat (cover) of the HPV
virus. This cover tricks the immune system and causes it to make antibodies that protect the
patient from infection. Because the vaccine contains none of the harmful viral genetic mate‐
rial, the vaccine is quite safe to administer to patients. While the vaccine is a huge step in
fighting a preventable and treatable cancer, it is not the end-all be-all in cervical cancer care.
There are over 30 types of HPV and the vaccines only protect against two or four strains,
respectively. There are still other strains of HPV that cause cancer, and it is possible that a
woman could already be infected by HPV when she was vaccinated. As a result, even with
vaccination routine Pap tests or other cervical cancer screening tests are still necessary.
4.1.1. Vaccine implementation in the developed countries
In developed countries, the widespread use of cervical "Pap smear" screening programs has
reduced the incidence of invasive cervical cancer by 50% or more. Current preventive vac‐
cines reduce, but do not eliminate the chance of getting cervical cancer. Therefore, experts
recommend that women combine the benefits of both programs by seeking regular Pap
smear screening, even after vaccination.
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Country Vaccine implementation
Australia Commencing in 2007 The Australian federal government began funding a voluntary program to
make Gardasil available free of charge to women aged 12–26 for a period of two years, with an
ongoing vaccination program for 12- and 13-year-olds as part of the pre-existing high school
vaccination program. The Australian government and the Pharmaceutical Benefits Scheme (PBS)
have approved the vaccine for use, and in 2007 began a nationwide vaccination program free of
charge to schoolgirls in years 7 to 12. Australia also approved Gardasil for boys 9–15 years old, but
Australia is not providing government funding for vaccinating boys.
Canada Canada has approved use of Gardasil. Free vaccinations to protect women against HPV were slated
to begin in September 2007 and will be offered to girls ages 11–14.
Denmark Introduced in Denmark from 1 January 2009 as part of the Danish Childhood Vaccination program.
France On July 17, 2007, France issued a directive authorizing state-aided voluntary vaccination for girls
aged 14–23 years who have not yet become sexually active, or have been sexually active for less
than a year.
Germany and Italy On March 26, 2007, early approval for Gardasil vaccinations was granted in both Germany and Italy.
Greece On February 12, 2007, Greece made HPV vaccination mandatory for girls entering gymnasion (7th
grade). All vaccines including hepatitis B are mandatory and are supplied free to everyone in Greece,
with parents being allowed to opt out of vaccinating their kids. Cervarix and Gardasil are supplied
free to all girls and women between the ages of 12 and 26.
Norway In Norway, starting from the fall of 2009, HPV vaccination was introduced into the national
immunization program, for girls aged 12–13. In March 2010, 57% of all girls born in 1997 had
received the first dose of the vaccine
South Korea On July 27, 2007, South Korean government approved Gardasil for use in girls and women aged 9 to
26 and boys aged 9 to 15.Approval for use in boys was based on safety and immunogenicity but not
efficacy.
Sweden In Sweden, starting January 1, 2010, girls born in 1999 or later and in the ages 10 to 12 can receive a
free HPV vaccine.
United Kingdom In the UK the vaccine is licensed for girls aged 9 to 15, for women aged 16 to 26, and for boys aged
9–15.HPV vaccination with cervarix was introduced into the national immunization program in
September 2008, for girls aged 12–13 across the UK. A two-year catch up campaign started in
Autumn 2009 to vaccinate all girls up to 18 years of age. Catch up vaccination will be offered to:
girls aged between 16 and 18 from autumn 2009, and girls aged between 15 and 17 from autumn
2010.By the end of the catch up campaign, all girls under 18 will have been offered the HPV vaccine.
United States According to the US Centers for Disease Control and Prevention (CDC), getting as many girls
vaccinated as early and as quickly as possible will reduce the cases of cervical cancer among middle-
aged women in 30 to 40 years and reduce the transmission of this highly communicable infection.
Source: European Cervical Cancer Association; American Cancer Society
Table 3. Vaccine implementation by various developed countries
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4.2. Cervical cancer screening: Secondary prevention
The objective of cervical cancer screening is to reduce both incidence and mortality. A suc‐
cessful screening program detects early, pre invasive lesions during the preclinical detecta‐
ble phase and is able to reduce deaths by preventing the occurrence of invasive cancer.
Diagnostic assessment requires colposcopy examination, with assessment of morphological
features of the cervix as well as histological evaluation. Over the past five decades, wide‐
spread access to cervical screening and early treatment has been a cornerstone of basic re‐
productive health services for women in wealthy countries. The Papanicolaou test or “Pap
smear” has significantly reduced the burden of cervical cancer in developed countries pro‐
gram (Hristova & Hakama, 1997; Duguid, Duncan, & Currie, 1985; Taylor et al., 2001).
In resource-rich settings, women are usually able to make repeated visits to seek screening,
diagnosis and treatment in clinics. The health system is equipped with skilled lab techni‐
cians, referral systems and clinicians capable of effectively managing this disease. It is esti‐
mated that regular screening reduces the risk of cancer by 80% to 98% (Olesen, 1988; WHO
1986). Organized screening programs for cervical cancer using Pap smears have been shown
to be more effective than opportunistic or non-organized screening. Opportunistic screening
typically misses the women at greatest risk (Anttila et al., 2004). Studies show that if a wom‐
an is screened only once in her lifetime between the ages of 30 to 40 it would reduce her
lifetime risk of cervical cancer between 25-36%.
In Finland, the population-based cervical cancer screening program which began in 1963
achieved a 60% reduction in the incidence of cancer at 10 years (Nieminen, Kallio & Haka‐
ma, 1995). In Norway, a population-based nationwide cervical cancer screening program
was introduced in 1995. Two years later the incidence of invasive cancer was 22% lower
(Nygard, Skare & Thoresen, 2002). In the United Kingdom the incidence of cervical cancer in
women aged 20-69 years fell by 33% between 1991-1993 and 1998-2000; mortality fell by 36%
over the same period (Canfell, Sitas & Beral, 2006). In Sweden, for example, the overall inci‐
dence of cervical cancer declined by 67% over a 40-year period, from 20 cases per 100 000
women (world standard rate) in 1965 to 6.6 cases per 100 000 women in 2005. Conversely,
the incidence of invasive cancer increased in an area of Denmark where organized screening
had been discontinued (Lynge, 1998). Other screening methods include direct visualization
of the cervix, liquidbased cytology and HPV screening.
A number of National guidelines are currently moving towards less frequent smear tests
(once every 3-5 years) since the cervical lesions develop fairly slowly after several years.
Women with high grade lesions of the cervix are further evaluated using colposcopy, biopsy
and subsequent treatment of confirmed lesions. The women with low grade lesions are gen‐
erally advised to return for routine follow up smears. Organized programs with systematic
call recall and follow up showed greatest effect in Finland and Iceland using fewer resources
compared to USA where they are successful but more resources used (Sankaranarayanan,
Budukh, & Rajkumar, 2001). Since progression to cervical cancer occurs after several years
and the low grade lesions tend to regress spontaneously or may not progress, high frequen‐
cy of screening would help in detection of previously missed high-grade lesion of the cervix.
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Current procedures that involve screening women once every 1-5yrs have considerable cost
and resource implications.
4.2.1. Status of cervical screening in the European Union
Almost all EU countries have a screening policy for cervical cancer. However, there are ma‐
jor variations in how the screening is organized, the type of screening activities, the targeted
age range and the recommended screening interval, as well as payment strategies. A review
in 2004 (Mackay et al, 2006) showed that national screening programs were in place in the
Nordic countries, the United Kingdom, Latvia, Slovenia, the Netherlands and Hungary. Re‐
gional screening programs were operational in Spain, Portugal, Italy, Romania, Czech Re‐
public, Austria and Belgium. Pilot programs existed in France, Greece, Ireland and Estonia.
No population-based screening program was in place in Germany, although there was a
screening policy.
The recommended screening interval ranges between three and five years in most EU coun‐
tries for which information is available. Some countries or regions recommend an excessive
number of smears, with consequent potential for over diagnosis and overtreatment. Similar‐
ly, the population covered by the screening programs varied between 30% in Slovenia and
100% in the Nordic countries and Italy (Anttila et al., 2004).EU recommendations state that
cervical cancer screening should be offered on a population basis in organized screening
programs. Pap smear screening for cervical abnormalities should start by the age of 30 (at
the latest) and definitely not before the age of 20 (Council of the European Union, 2003). De‐
tailed European guidelines on quality assurance screening programmes have been devel‐
oped (European Cancer Network, 2007). Centralized data systems are essential for
monitoring and evaluating the effectiveness of such programs.
4.2.2. Status of cervical screening in the US
The United States Preventive Services Task Force supports screening every 5 years in those
who are between 30 and 65 years when cytology is used in combination with HPV testing.
The American Cancer Society recommends these screening guidelines for most adults: (i)
cervical cancer screening (testing) should begin at age 21; (ii) women under age 21 should
not be tested;(iii) women between ages 21 and 29 should have a Pap test every 3 years. Now
there is also a test called the HPV test. HPV testing should not be used in this age group
unless it is needed after an abnormal Pap test result; (iv) women between the ages of 30 and
65 should have a Pap test plus an HPV test (called “co-testing”) every 5 years; (v) women
over age 65 who have had regular cervical cancer testing with normal results should not be
tested for cervical cancer. Once testing is stopped, it should not be started again; (vi) women
with a history of a serious cervical pre-cancer should continue to be tested for at least 20
years after that diagnosis, even if testing continues past age 65; (vii) a woman who has had
her uterus removed (and also her cervix) for reasons not related to cervical cancer and who
has no history of cervical cancer or serious pre-cancer should not be tested; (viii) a woman
who has been vaccinated against HPV should still follow the screening recommendations
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for her age group. Some women – because of their history – may need to have a different
screening schedule for cervical cancer.
5. Conclusions
Cervical cancer is a unique public health challenge. It is gender-specific, caused by a sexual‐
ly transmitted virus, and its primary and secondary prevention strategies target opposite
ends of a wide age spectrum. The natural history of cervical cancer is well studied, and
screening programs that identify pre-cancers early have been successful at significantly re‐
ducing disease, albeit at significant financial cost. Primary prevention through HPV vaccina‐
tion will most likely be one of the most remarkable medical advances of this century.
Together, secondary prevention through screening and early treatment and primary preven‐
tion through early adolescent vaccination could provide a comprehensive strategy for a
long-term vision to eliminate cervical cancer. Thanks to the effectiveness of national screen‐
ing programs, the incidence and mortality rates for cervical cancer have declined dramati‐
cally in developed countries. Vaccination against HPV infection could reduce the risk of
infection and, most importantly, decrease the incidence of cervical cancer. Therefore, beating
cervical cancer in the developed countries is not a dream in the far future, it is happening
today.
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